Diabetic combined kidney disease or heart failure patients benefited more from SGLT1/2 inhibitors

In the past ten years, the protective effect of sodium-glucose co-transport protein 2 (SGLT2) inhibitors on cardiovascular and kidney function in diabetic patients has been proved.
recently, the American Heart Association (AHA) 2020 Scientific Conference and the New England Journal of Medicine published two studies of SGLT1/2 double inhibitor sotagliflozin in diabetic patients, adding important evidence.
as a double inhibitor, sotagliflozin's SGLT2 inhibition helps the body lower blood sugar through urine, and SGLT1 inhibits blood sugar through the digestive tract.
Dr Deepak L. Bhatt, a cardiologist at Brigham and Women's Hospital and co-author of the two studies, said: "SCORED is the first trial to show that SGLT2 inhibitors are beneficial to all patients with varying degrees of proteinuria, and the first to show that SGLT2 inhibitors are beneficial for stroke prevention.
SOLOIST is the first large randomized trial to demonstrate the safety and effectiveness of initiating SGLT2 inhibitor therapy in hospitalized patients with acute heart failure, and it does change this field and support the early initiation therapy of SGLT2 inhibitors.
" Screenshot Source: The New England Journal of MedicineSCORED trial was conducted in patients with type 2 diabetes combined with the risk of chronic kidney and cardiovascular disease to assess the effects of sotagliflozin on cardiovascular risk.
from other previous trials, which included all patients with varying degrees of proteinuria.
10,584 patients received sotagliflozin or placebo in a random group of 10,584 patients.
follow-up time was 16 months.
data show that sotagliflozin significantly reduced the overall risk of cardiovascular death, hospitalization for heart failure, or emergency care due to heart failure by 26 percent, with similar benefits regardless of the patient's level of proteinuria.
same time, sotagliflozin reduced the overall risk of cardiovascular death, non-fatal myocardial infarction or stroke by 16 percent, and the risk of all heart attacks or strokes by 32 percent and 34 percent, respectively.
Screenshot Source: The New England Journal of MedicineSOLOIST trial assesses the risk of death from cardiovascular causes and re-hospitalization and emergency care due to type 2 diabetes and recent heart failure.
a total of 1,222 patients received sotagliflozin or placebo in a random group of 1:1.
48.8 per cent and 51.2 per cent of patients in the trial group received the first dose of sotagliflozin before or on average 2 days after discharge.
the mid-level follow-up period is Sept.
data showed a significant 33 percent reduction in the risk of cardiovascular death and re-hospitalization and emergency care due to heart failure in patients in the sotagliflozin group, with similar benefits regardless of whether patients retained heart failure for lower shot fractions or shot blood fractions.
showed that people with type 2 diabetes were safe and effective before they were discharged from the hospital with acute heart failure.
Deepak L. Bhatt said, "Based on the results of these two large trials, together with other recent data on these drugs, most patients with type 2 diabetes with combined kidney disease or heart failure should use SGLT2 inhibitors."
" References . . . Deepak L. Bhatt , et al., (2020). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med, DOI: 10.1056/NEJMoa2030186[2] Deepak L. Bhatt , et al., (2020). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med, DOI: 10.1056/NEJMoa2030183[3] SCORED and SOLOIST trials add to evidence for treating diabetes with SGLT2 inhibitors. Retrieved November 18, 2020, from